Gossamer bio announces third quarter 2023 financial results and provides business update

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced its financial results for the third quarter ended september 30, 2023, and provided a business update. “we are pleased with the progress our team has made with the launch of the seralutinib phase 3 prosera study. with sites opening up across the globe, w.
GOSS Ratings Summary
GOSS Quant Ranking